MedTrace Logo

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

NCT03632668 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-07-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.

Conditions

Interventions

DRUG

AD-2071 10/20mg

AD-2071 10/20 mg tablet

DRUG

AD-2072 80/5mg

AD-2072 80/5mg tablet

DRUG

AD-2071 10/20mg + AD2072 80/5mg

AD-2071 10/20 mg + AD-2072 80/5mg tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, M.D.,Ph.D · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2019-01-24
Completion
2019-01-24

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03632668 on ClinicalTrials.gov